The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 07, 2024

Filed:

Oct. 22, 2019
Applicant:

Agex Therapeutics, Inc., Alameda, CA (US);

Inventor:

Basil M. Hantash, East Palo Alto, CA (US);

Assignee:

AgeX Therapeutics, Inc., Alameda, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A01K 67/0271 (2024.01); A61K 35/12 (2015.01); A61K 35/28 (2015.01); A61K 35/33 (2015.01); A61K 35/407 (2015.01); A61K 35/44 (2015.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12N 5/073 (2010.01); G01N 33/566 (2006.01); G01N 33/569 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56977 (2013.01); A01K 67/0271 (2013.01); A61K 35/12 (2013.01); A61K 35/28 (2013.01); A61K 35/33 (2013.01); A61K 35/407 (2013.01); A61K 35/44 (2013.01); C07K 14/70539 (2013.01); C07K 16/28 (2013.01); C12N 5/0603 (2013.01); G01N 33/566 (2013.01); G01N 33/6893 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/025 (2013.01); C12N 2510/00 (2013.01); G01N 2333/705 (2013.01); G01N 2333/71 (2013.01); G01N 2800/245 (2013.01);
Abstract

Disclosed herein are methods for producing genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.


Find Patent Forward Citations

Loading…